
Intellia Therapeutics (NTLA) Stock Forecast & Price Target
Intellia Therapeutics (NTLA) Analyst Ratings
Bulls say
Intellia Therapeutics is positioned favorably due to significant improvements observed in patient quality of life metrics and functional capabilities following treatment with its gene editing therapies, particularly NTLA-2002. The company has successfully demonstrated substantial reductions in angioedema attacks and improved overall health outcomes, which indicate the potential for transformative therapeutic options in genetically defined diseases. Additionally, the ongoing collaborations with established industry players such as Regeneron and Novartis not only bolster Intellia's research pipeline but also enhance its commercial prospects, contributing to a positive long-term growth outlook.
Bears say
Intellia Therapeutics is facing a challenging landscape characterized by significant regulatory risks, as the potential failure to obtain approvals for its therapies could lead to downward revisions in its financial projections. The company's net present value (NPV) modeling reflects a cautious outlook, with a reduced NPV/share attributed to factors like sentiment, the engineered immune cell platform, and the in vivo therapeutics platform, highlighting concerns over future performance. Additionally, competitive threats from advanced treatment options, such as Alnylam's next-generation RNAi asset, pose further risks to Intellia's market positioning and long-term growth potential.
This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction
Start investing in Intellia Therapeutics (NTLA)
Order type
Buy in
Order amount
Est. shares
0 shares